Lymphoma Clinical Trials in Atlanta

Showing 241-260 of 296 trials

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

NCT00498914

A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155

Lymphoma, Large-Cell, DiffuseLymphoma, B-Cell Refractory

Astellas Pharma Inc41 participantsStarted Jun 2007

Beverly Hills, California, United States • Palo Alto, California, United States • Aurora, Colorado, United States +19 more locations

COMPLETEDPHASE1< 1 mile

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

NCT00085150

RATIONALE: LMB-2 immunotoxin can locate cancer cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of LMB-2 immunotoxin in treating young patients with relapsed or refractory leukemia or lymphoma.

LeukemiaLymphoma

National Cancer Institute (NCI)40 participantsStarted Apr 2004

Atlanta, Georgia, United States • Baltimore, Maryland, United States • Bethesda, Maryland, United States +2 more locations

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

Lymphoma Trials in Other Cities

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

Imexon for Relapsed Follicular and Aggressive Lymphomas

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

Other Conditions in Atlanta